Bristol Glucophage Strategy Lifts Stock As Sector Wilts From Medicare Redux
Executive Summary
Bristol-Myers Squibb's diabetes portfolio was a sweetener for the Street as the stock turned in one of the few positive showings among big pharma companies during a quarter marked by increasing political rhetoric over a Medicare drug benefit.